nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

01.02.2014

Antiplatelet Therapy: Targeting the TxA₂ Pathway

verfasst von: P. Fontana, A. Zufferey, Y. Daali, J.-L. Reny

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The thromboxane (Tx) A₂ pathway is a major contributor to the amplification of the initial platelet activation process. TxA₂ mediates its effect through the thromboxane prostanoid (TP) receptor that is expressed not only in platelets, but also in endothelial cells, macrophages, and monocytes, and thus contributes to the development of atherosclerotic lesions. The TxA₂ pathway is therefore a major target in the treatment of cardiovascular disease. Aspirin—the most widely used antiplatelet drug—is very effective at inhibiting platelet-derived TxA₂ synthesis. However, aspirin’s effects can be overcome by several other soluble agonists such as isoprostanes, which are aspirin-insensitive ligands of the TP receptor that are preferentially produced in diabetes mellitus. Other drugs, with either inhibitory effects on Tx synthase or antagonist effects on TP, have been developed with the hope of providing a better, more complete inhibition of the TxA₂ pathway.

Hansson, G. K., Robertson, A. K., & Soderberg-Naucler, C. (2006). Inflammation and atherosclerosis. Annual Review of Pathology, 1, 297–329. doi:10.1146/annurev.pathol.1.110304.100100.PubMedCrossRef

Libby, P. (2012). Inflammation in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 32(9), 2045–2051. doi:10.1161/ATVBAHA.108.179705.PubMedCentralPubMedCrossRef

Coppinger, J. A., & Maguire, P. B. (2007). Insights into the platelet releasate. Current Pharmaceutical Design, 13(26), 2640–2646.PubMedCrossRef

Hansson, G. K. (2005). Inflammation, atherosclerosis, and coronary artery disease. The New England Journal of Medicine, 352(16), 1685–1695.PubMedCrossRef

Kirkby, N. S., Leadbeater, P. D., Chan, M. V., Nylander, S., Mitchell, J. A., & Warner, T. D. (2011). Antiplatelet effects of aspirin vary with level of P2Y(1)(2) receptor blockade supplied by either ticagrelor or prasugrel. Journal of Thrombosis and Haemostasis, 9(10), 2103–2105. doi:10.1111/j.1538-7836.2011.04453.x.PubMedCentralPubMedCrossRef

Armstrong, P. C., Leadbeater, P. D., Chan, M. V., Kirkby, N. S., Jakubowski, J. A., Mitchell, J. A., et al. (2011). In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. Journal of Thrombosis and Haemostasis, 9(3), 552–561. doi:10.1111/j.1538-7836.2010.04160.x.PubMedCentralPubMedCrossRef

Maclouf, J., Folco, G., & Patrono, C. (1998). Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thrombosis and Haemostasis, 79(4), 691–705.PubMed

Hamberg, M., Svensson, J., & Samuelsson, B. (1975). Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Sciences of the United States of America, 72(8), 2994–2998.PubMedCentralPubMedCrossRef

Smyth, E. M. (2010). Thromboxane and the thromboxane receptor in cardiovascular disease. Journal of Clinical Lipidology, 5(2), 209–219. doi:10.2217/CLP.10.11.CrossRef

10.

Ekambaram, P., Lambiv, W., Cazzolli, R., Ashton, A. W., & Honn, K. V. (2011). The thromboxane synthase and receptor signaling pathway in cancer: an emerging paradigm in cancer progression and metastasis. Cancer and Metastasis Reviews, 30(3–4), 397–408. doi:10.1007/s10555-011-9297-9.PubMedCrossRef

11.

Sakariassen, K. S., Alberts, P., Fontana, P., Mann, J., Bounameaux, H., & Sorensen, A. S. (2009). Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases. Future Cardiology, 5(5), 479–493. doi:10.2217/fca.09.33.PubMedCrossRef

12.

Rocca, B., Secchiero, P., Ciabattoni, G., Ranelletti, F. O., Catani, L., Guidotti, L., et al. (2002). Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proceedings of the National Academy of Sciences of the United States of America, 99(11), 7634–7639. doi:10.1073/pnas.112202999.PubMedCentralPubMedCrossRef

13.

McAdam, B. F., Mardini, I. A., Habib, A., Burke, A., Lawson, J. A., Kapoor, S., et al. (2000). Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. The Journal of Clinical Investigation, 105(10), 1473–1482. doi:10.1172/JCI9523.PubMedCentralPubMedCrossRef

14.

Chandrasekharan, N. V., Dai, H., Roos, K. L., Evanson, N. K., Tomsik, J., Elton, T. S., et al. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences of the United States of America, 99(21), 13926–13931. doi:10.1073/pnas.162468699.PubMedCentralPubMedCrossRef

15.

Botting, R., & Ayoub, S. S. (2005). COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 72(2), 85–87. doi:10.1016/j.plefa.2004.10.005.PubMedCrossRef

16.

Capra, V., Back, M., Barbieri, S. S., Camera, M., Tremoli, E., & Rovati, G. E. (2013). Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Medicinal Research Reviews, 33(2), 364–438. doi:10.1002/med.21251.PubMedCrossRef

17.

Audoly, L. P., Rocca, B., Fabre, J. E., Koller, B. H., Thomas, D., Loeb, A. L., et al. (2000). Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation, 101(24), 2833–2840.PubMedCrossRef

18.

Narumiya, S. (1994). Prostanoid receptors. Structure, function, and distribution. Annals of the New York Academy of Sciences, 744, 126–138.PubMedCrossRef

19.

Nusing, R. M., Hirata, M., Kakizuka, A., Eki, T., Ozawa, K., & Narumiya, S. (1993). Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. The Journal of Biological Chemistry, 268(33), 25253–25259.PubMed

20.

Unoki, M., Furuta, S., Onouchi, Y., Watanabe, O., Doi, S., Fujiwara, H., et al. (2000). Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association a T924C polymorphism in the thromboxane A2 receptor gene. Human Genetics, 106(4), 440–446.PubMedCrossRef

21.

Fontana, P., Gandrille, S., Remones, V., Dupont, A., Reny, J. L., Aiach, M., et al. (2006). Identification of functional polymorphisms of the thromboxane A2 receptor gene in healthy volunteers. Thrombosis and Haemostasis, 96(3), 356–360.PubMed

22.

Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S., et al. (1991). Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature, 349(6310), 617–620.PubMedCrossRef

23.

Raychowdhury, M. K., Yukawa, M., Collins, L. J., McGrail, S. H., Kent, K. C., & Ware, J. A. (1994). Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. The Journal of Biological Chemistry, 269(30), 19256–19261.PubMed

24.

Hirata, T., Ushikubi, F., Kakizuka, A., Okuma, M., & Narumiya, S. (1996). Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. The Journal of Clinical Investigation, 97(4), 949–956.PubMedCentralPubMedCrossRef

25.

Habib, A., FitzGerald, G. A., & Maclouf, J. (1999). Phosphorylation of the thromboxane receptor alpha, the predominant isoform expressed in human platelets. The Journal of Biological Chemistry, 274(5), 2645–2651.PubMedCrossRef

26.

Nakahata, N. (2008). Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacology and Therapeutics, 118(1), 18–35. doi:10.1016/j.pharmthera.2008.01.001.PubMedCrossRef

27.

Patrono, C. (1994). Aspirin as an antiplatelet drug. The New England Journal of Medicine, 330(18), 1287–1294.PubMedCrossRef

28.

Rocca, B., Santilli, F., Pitocco, D., Mucci, L., Petrucci, G., Vitacolonna, E., et al. (2012). The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. Journal of Thrombosis and Haemostasis, 10(7), 1220–1230. doi:10.1111/j.1538-7836.2012.04723.x.PubMedCrossRef

29.

Pascale, S., Petrucci, G., Dragani, A., Habib, A., Zaccardi, F., Pagliaccia, F., et al. (2012). Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood, 119(15), 3595–3603. doi:10.1182/blood-2011-06-359224.PubMedCrossRef

30.

Davi, G., Santilli, F., & Vazzana, N. (2012). Thromboxane receptors antagonists and/or synthase inhibitors. Handbook of Experimental Pharmacology, 210, 261–286. doi:10.1007/978-3-642-29423-5_11.PubMedCrossRef

31.

Rolin, S., Masereel, B., & Dogne, J. M. (2006). Prostanoids as pharmacological targets in COPD and asthma. European Journal of Pharmacology, 533(1–3), 89–100. doi:10.1016/j.ejphar.2005.12.058.PubMedCrossRef

32.

Zhang, J., Yang, J., Chang, X., Zhang, C., Zhou, H., & Liu, M. (2012). Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials. Neurological Research, 34(4), 346–353. doi:10.1179/1743132812Y.0000000022.PubMedCrossRef

33.

FitzGerald, G. A., Reilly, I. A., & Pedersen, A. K. (1985). The biochemical pharmacology of thromboxane synthase inhibition in man. Circulation, 72(6), 1194–1201.PubMedCrossRef

34.

Cayatte, A. J., Du, Y., Oliver-Krasinski, J., Lavielle, G., Verbeuren, T. J., & Cohen, R. A. (2000). The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 20(7), 1724–1728.PubMedCrossRef

35.

Viles-Gonzalez, J. F., Fuster, V., Corti, R., Valdiviezo, C., Hutter, R., Corda, S., et al. (2005). Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition—a magnetic resonance imaging study. European Heart Journal, 26(15), 1557–1561. doi:10.1093/eurheartj/ehi175.PubMedCrossRef

36.

Gaussem, P., Reny, J. L., Thalamas, C., Chatelain, N., Kroumova, M., Jude, B., et al. (2005). The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. Journal of Thrombosis and Haemostasis, 3(7), 1437–1445.PubMedCrossRef

37.

Fiessinger, J. N., Bounameaux, H., Cairols, M. A., Clement, D. L., Coccheri, S., Fletcher, J. P., et al. (2010). Thromboxane antagonism with terutroban in peripheral arterial disease: the TAIPAD study. Journal of Thrombosis and Haemostasis, 8(11), 2369–2376. doi:10.1111/j.1538-7836.2010.04020.x.PubMedCrossRef

38.

Bal Dit Sollier, C., Crassard, I., Simoneau, G., Bergmann, J. F., Bousser, M. G., & Drouet, L. (2009). Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovascular Diseases, 28(5), 505–513. doi:10.1159/000236915.PubMedCrossRef

39.

Bousser, M. G., Amarenco, P., Chamorro, A., Fisher, M., Ford, I., Fox, K. M., et al. (2011). Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet, 377(9782), 2013–2022. doi:10.1016/S0140-6736(11)60600-4.PubMedCrossRef

40.

Meadows, T. A., & Bhatt, D. L. (2007). Clinical aspects of platelet inhibitors and thrombus formation. Circulation Research, 100(9), 1261–1275. doi:10.1161/01.RES.0000264509.36234.51.PubMedCrossRef

41.

The Ridogrel Versus Aspirin Patency Trial (RAPT). (1994). Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation, 89(2), 588–595.CrossRef

42.

Neri Serneri, G. G., Coccheri, S., Marubini, E., & Violi, F. (2004). Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. European Heart Journal, 25(20), 1845–1852.PubMedCrossRef

43.

Fontana, P., & Reny, J. L. (2007). New antiplatelet strategies in atherothrombosis and their indications. European Journal of Vascular and Endovascular Surgery, 34(1), 10–17.PubMedCrossRef

44.

Fontana, P., Alberts, P., Sakariassen, K. S., Bounameaux, H., Meyer, J. P., & Santana Sorensen, A. (2011). The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. Journal of Thrombosis and Haemostasis. doi:10.1111/j.1538-7836.2011.04446.x.

45.

Tello-Montoliu, A., Rollini, F., Desai, B., Pasqualino, G., Patel, R., Sorensen, A. S., et al. (2012). Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. Journal of Thrombosis and Thrombolysis, 34(3), 297–299. doi:10.1007/s11239-012-0795-6.PubMedCrossRef

46.

Richardson, A., Sakariassen, K. S., Meyer, J. P., Alberts, P., & Sorensen, A. S. (2013). Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation. European Journal of Clinical Pharmacology, 69(3), 459–465. doi:10.1007/s00228-012-1348-9.PubMedCrossRef

47.

Rollini, F., Tello-Montoliu, A., Patel, R., Darlington, A., Wilson, R. E., Franchi, F., et al. (2013). Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. Journal of Thrombosis and Thrombolysis. doi:10.1007/s11239-013-0979-8.

48.

Sakariassen, K. S., Femia, E. A., Daray, F. M., Podda, G. M., Razzari, C., Pugliano, M., et al. (2012). EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin. Thrombosis Research, 130(5), 746–752. doi:10.1016/j.thromres.2012.08.309.PubMedCrossRef

49.

Elwood, P. C., Cochrane, A. L., Burr, M. L., Sweetnam, P. M., Williams, G., Welsby, E., et al. (1974). A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. British Medical Journal, 1(5905), 436–440.PubMedCrossRef

50.

Steg, P. G., James, S. K., Atar, D., Badano, L. P., Blomstrom-Lundqvist, C., Borger, M. A., et al. (2012). ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 33(20), 2569–2619. doi:10.1093/eurheartj/ehs215.PubMedCrossRef

51.

Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373(9678), 1849–1860. doi:10.1016/S0140-6736(09)60503-1.PubMedCrossRef

52.

Fowkes, F. G., Price, J. F., Stewart, M. C., Butcher, I., Leng, G. C., Pell, A. C., et al. (2010). Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA, 303(9), 841–848. doi:10.1001/jama.2010.221.PubMedCrossRef

53.

Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Z., Verschuren, M., et al. (2012). European guidelines on cardiovascular disease prevention in clinical practice (version, 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European Heart Journal, 33(13), 1635–1701. doi:10.1093/eurheartj/ehs092.PubMedCrossRef

54.

U.S. Preventive Services Task Force. (2009). Aspirin for the prevention of cardiovascular disease: recommendation statement. Annals of Internal Medicine, 150(6), 396–404.CrossRef

55.

De Berardis, G., Sacco, M., Strippoli, G. F., Pellegrini, F., Graziano, G., Tognoni, G., et al. (2009). Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ, 339, b4531. doi:10.1136/bmj.b4531.PubMedCentralPubMedCrossRef

56.

Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377(9759), 31–41. doi:10.1016/S0140-6736(10)62110-1.PubMedCrossRef

57.

Brighton, T. A., Eikelboom, J. W., Mann, K., Mister, R., Gallus, A., Ockelford, P., et al. (2012). Low-dose aspirin for preventing recurrent venous thromboembolism. The New England Journal of Medicine, 367(21), 1979–1987. doi:10.1056/NEJMoa1210384.PubMedCrossRef

58.

Helgason, C. M., Tortorice, K. L., Winkler, S. R., Penney, D. W., Schuler, J. J., McClelland, T. J., et al. (1993). Aspirin response and failure in cerebral infarction. Stroke, 24(3), 345–350.PubMedCrossRef

59.

Michelson, A. D., Cattaneo, M., Eikelboom, J. W., Gurbel, P., Kottke-Marchant, K., Kunicki, T. J., et al. (2005). Aspirin resistance: position paper of the Working Group on Aspirin Resistance. Journal of Thrombosis and Haemostasis, 3(6), 1309–1311.PubMedCrossRef

60.

Patrono, C., Garcia Rodriguez, L. A., Landolfi, R., & Baigent, C. (2005). Low-dose aspirin for the prevention of atherothrombosis. The New England Journal of Medicine, 353(22), 2373–2383.PubMedCrossRef

61.

Hovens, M. M., Snoep, J. D., Eikenboom, J. C., van der Bom, J. G., Mertens, B. J., & Huisman, M. V. (2007). Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. American Heart Journal, 153(2), 175–181.PubMedCrossRef

62.

Eikelboom, J. W., Hirsh, J., Weitz, J. I., Johnston, M., Yi, Q., & Yusuf, S. (2002). Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 105(14), 1650–1655.PubMedCrossRef

63.

Snoep, J. D., Hovens, M. M., Eikenboom, J. C., van der Bom, J. G., & Huisman, M. V. (2007). Association of laboratory-defined aspirin resistance with a higer risk of recurrent cardiovascular events. A systematic review and meta-analysis. Archives of Internal Medicine, 167(15), 1593–1599.PubMedCrossRef

64.

Reny, J. L., De Moerloose, P., Dauzat, M., & Fontana, P. (2008). Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 6(3), 444–450. doi:10.1111/j.1538-7836.2008.02897.x.PubMedCrossRef

65.

Reny, J. L., Berdague, P., Poncet, A., Barazer, I., Nolli, S., Fabbro-Peray, P., et al. (2012). Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events Study. Circulation, 125(25), 3201–3210. doi:10.1161/CIRCULATIONAHA.111.085464.PubMedCrossRef

66.

Pettersen, A. A., Seljeflot, I., Abdelnoor, M., & Arnesen, H. (2012). High on-aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). Journal of the American Heart Association, 1(3), e000703. doi:10.1161/JAHA.112.000703.PubMedCentralPubMedCrossRef

67.

Stone, G. W., Witzenbichler, B., Weisz, G., Rinaldi, M. J., Neumann, F. J., Metzger, D. C., et al. (2013). Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, 382(9892), 614–623. doi:10.1016/S0140-6736(13)61170-8.PubMedCrossRef

68.

Capodanno, D., Patel, A., Dharmashankar, K., Ferreiro, J. L., Ueno, M., Kodali, M., et al. (2011). Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circulation. Cardiovascular Interventions, 4(2), 180–187. doi:10.1161/CIRCINTERVENTIONS.110.960187.PubMedCrossRef

69.

Faraday, N., Yanek, L. R., Mathias, R., Herrera-Galeano, J. E., Vaidya, D., Moy, T. F., et al. (2007). Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation, 115(19), 2490–2496.PubMedCrossRef

70.

Kunicki, T. J., Williams, S. A., & Nugent, D. J. (2012). Genetic variants that affect platelet function. Current Opinion in Hematology, 19(5), 371–379. doi:10.1097/MOH.0b013e3283567526.PubMedCrossRef

71.

Johnson, A. D., Yanek, L. R., Chen, M. H., Faraday, N., Larson, M. G., Tofler, G., et al. (2010). Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nature Genetics, 42(7), 608–613. doi:10.1038/ng.604.PubMedCentralPubMedCrossRef

72.

Zimmerman, G. A., & Weyrich, A. S. (2008). Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(3), s17–s24. doi:10.1161/ATVBAHA.107.160218.PubMedCentralPubMedCrossRef

73.

Kondkar, A. A., Bray, M. S., Leal, S. M., Nagalla, S., Liu, D. J., Jin, Y., et al. (2010). VAMP8/endobrevin is overexpressed in hyperreactive human platelets: suggested role for platelet microRNA. Journal of Thrombosis and Haemostasis, 8(2), 369–378. doi:10.1111/j.1538-7836.2009.03700.x.PubMedCentralPubMedCrossRef

74.

Edelstein, L. C., & Bray, P. F. (2011). MicroRNAs in platelet production and activation. Blood, 117(20), 5289–5296. doi:10.1182/blood-2011-01-292011.PubMedCrossRef

75.

Nagalla, S., Shaw, C., Kong, X., Kondkar, A. A., Edelstein, L. C., Ma, L., et al. (2011). Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood, 117(19), 5189–5197. doi:10.1182/blood-2010-09-299719.PubMedCrossRef

76.

Burkhart, J. M., Vaudel, M., Gambaryan, S., Radau, S., Walter, U., Martens, L., et al. (2012). The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood, 120(15), e73–e82. doi:10.1182/blood-2012-04-416594.PubMedCrossRef

77.

Mateos-Caceres, P. J., Macaya, C., Azcona, L., Modrego, J., Mahillo, E., Bernardo, E., et al. (2010). Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients. Thrombosis and Haemostasis, 103(1), 160–170. doi:10.1160/TH09-05-0290.PubMedCrossRef

78.

Lopez-Farre, A. J., Mateos-Caceres, P. J., Sacristan, D., Azcona, L., Bernardo, E., de Prada, T. P., et al. (2007). Relationship between vitamin D binding protein and aspirin resistance in coronary ischemic patients: a proteomic study. Journal of Proteome Research, 6(7), 2481–2487. doi:10.1021/pr060600i.PubMedCrossRef

79.

Bensimon, A., Heck, A. J., & Aebersold, R. (2012). Mass spectrometry-based proteomics and network biology. Annual Review of Biochemistry, 81, 379–405. doi:10.1146/annurev-biochem-072909-100424.PubMedCrossRef

80.

Zufferey, A., Ibberson, M., Reny, J. L., Xenarios, I., Sanchez, J. C., & Fontana, P. (2013). Unraveling modulators of platelet reactivity in cardiovascular patients using omics strategies: towards a network biology paradigm. Translational Proteomics, 1(1), 25–37.CrossRef

Titel: Antiplatelet Therapy: Targeting the TxA2 Pathway
verfasst von: P. Fontana
A. Zufferey
Y. Daali
J.-L. Reny
Publikationsdatum: 01.02.2014
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 1/2014
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-013-9529-1

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Impact of Mild Hypothermia on Platelet Responsiveness to Aspirin and Clopidogrel: an In Vitro Pharmacodynamic Investigation

Association of Thrombin Generation Potential with Platelet PAR-1 Regulation and P-Selectin Expression in Patients on Dual Antiplatelet Therapy

Gender and Anti-thrombotic Therapy: from Biology to Clinical Implications

Monocyte–Platelets Aggregates as Cellular Biomarker of Endothelium-Dependent Coronary Vasomotor Dysfunction in Patients with Coronary Artery Disease